{"id":43686,"date":"2025-10-17T15:11:51","date_gmt":"2025-10-17T07:11:51","guid":{"rendered":"https:\/\/flcube.com\/?p=43686"},"modified":"2025-10-17T15:11:52","modified_gmt":"2025-10-17T07:11:52","slug":"i%e2%80%91mab-announces-global-transformation-novabridge-rebranding-and-37-m-acquisition-of-vis%e2%80%91101","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43686","title":{"rendered":"I\u2011Mab Announces Global Transformation, NovaBridge Rebranding, and $37\u202fM Acquisition of VIS\u2011101"},"content":{"rendered":"\n<p><strong>I\u2011MAB Biopharma<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/IMAB:NASDAQ\">NASDAQ: IMAB<\/a>), a public company under the CBC Group, today revealed a strategic overhaul to become a <strong>global biotechnology platform<\/strong>. The company will rename itself <strong>NovaBridge Biosciences<\/strong> and pursue a dual initial public offering (IPO) on the Nasdaq and the Hong Kong Stock Exchange (HKEX). Concurrently, NovaBridge announced the acquisition of the bispecific ocular therapeutic <strong>VIS\u2011101<\/strong> through its newly\u2011formed subsidiary <strong>Visara<\/strong> and a licensing collaboration with <strong>Everest Medicines<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1952:HKG\">HKG: 1952<\/a>).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-1-global-platform-transformation-amp-dual-listing\">1. Global Platform Transformation &amp; Dual Listing<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rebranding<\/strong> \u2013 I\u2011Mab will change its corporate name to <strong>NovaBridge Biosciences<\/strong>, underscoring a shift from a single\u2011product focus to a diversified biotech platform.<\/li>\n\n\n\n<li><strong>IPO Strategy<\/strong> \u2013 The planned dual listing on Nasdaq and HKEX is designed to unlock broader capital markets, enhance liquidity, and provide dual-access to U.S. and Asian investors.<\/li>\n\n\n\n<li><strong>Strategic Growth<\/strong> \u2013 NovaBridge aims to build end\u2011to\u2011end capabilities\u2014from discovery to commercialization\u2014to accelerate access to innovative medicines across multiple therapeutic areas.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-2-acquisition-of-vis-101-through-visara\">2. Acquisition of VIS\u2011101 Through Visara<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Asset<\/strong> \u2013 <strong>VIS\u2011101<\/strong> is a bispecific biomolecule that simultaneously targets <strong>VEGF\u2011A<\/strong> and <strong>ANG\u20112<\/strong>, offering superior molecular activity compared with current anti\u2011VEGF therapies.<\/li>\n\n\n\n<li><strong>Clinical Value<\/strong> \u2013 Early data indicate more durable efficacy for patients with <strong>wet Age\u2011Related Macular Degeneration (wet AMD)<\/strong>, <strong>Diabetic Macular Edema (DME)<\/strong>, and <strong>Retinal Vein Occlusion (RVO)<\/strong>.<\/li>\n\n\n\n<li><strong>Transaction Structure<\/strong> \u2013 NovaBridge will fund Visara with <strong>$37\u202fmillion<\/strong> and receive equity from strategic partner <strong>AffaMed Therapeutics<\/strong>. The deal is expected to close this month, making NovaBridge the controlling shareholder of Visara and holder of global rights to VIS\u2011101.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-3-licensing-collaboration-with-everest-medicines\">3. Licensing Collaboration with Everest Medicines<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Letter of Intent<\/strong> \u2013 NovaBridge signed a LOI with <strong>Everest Medicines<\/strong> (1952.HK) for a joint licensing partnership covering <strong>Greater China<\/strong> and global clinical development of VIS\u2011101.<\/li>\n\n\n\n<li><strong>Strategic Impact<\/strong> \u2013 The collaboration leverages Everest\u2019s robust Chinese regulatory network and commercial infrastructure, positioning VIS\u2011101 for accelerated market entry in Asia.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-4-clinical-development-milestones\">4. Clinical Development Milestones<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Safety &amp; Dose Escalation<\/strong> \u2013 VIS\u2011101 has completed preliminary safety and dose\u2011escalation studies in the U.S. and China.<\/li>\n\n\n\n<li><strong>Phase\u202fII<\/strong> \u2013 A randomized, dose\u2011ranging Phase\u202fII study in China has finished, supporting the drug\u2019s efficacy profile.<\/li>\n\n\n\n<li><strong>Phase\u202fIII Readiness<\/strong> \u2013 The platform is on track for a Phase\u202fIII launch in 2026, with global development timelines aligned with the dual\u2011market IPO strategy.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>I\u2011MAB Biopharma (NASDAQ: IMAB), a public company under the CBC Group, today revealed a strategic&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43690,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[126,1164,182,72,28,976,4398],"class_list":["post-43686","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-everest-medicines","tag-hkg-1952","tag-i-mab-biopharma","tag-ipo","tag-multi-specific-antibodies","tag-nasdaq-imab","tag-novabridge-biosciences"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>I\u2011Mab Announces Global Transformation, NovaBridge Rebranding, and $37\u202fM Acquisition of VIS\u2011101 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"I\u2011MAB Biopharma (NASDAQ: IMAB), a public company under the CBC Group, today revealed a strategic overhaul to become a global biotechnology platform. The company will rename itself NovaBridge Biosciences and pursue a dual initial public offering (IPO) on the Nasdaq and the Hong Kong Stock Exchange (HKEX). Concurrently, NovaBridge announced the acquisition of the bispecific ocular therapeutic VIS\u2011101 through its newly\u2011formed subsidiary Visara and a licensing collaboration with Everest Medicines (HKG: 1952).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43686\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"I\u2011Mab Announces Global Transformation, NovaBridge Rebranding, and $37\u202fM Acquisition of VIS\u2011101\" \/>\n<meta property=\"og:description\" content=\"I\u2011MAB Biopharma (NASDAQ: IMAB), a public company under the CBC Group, today revealed a strategic overhaul to become a global biotechnology platform. The company will rename itself NovaBridge Biosciences and pursue a dual initial public offering (IPO) on the Nasdaq and the Hong Kong Stock Exchange (HKEX). Concurrently, NovaBridge announced the acquisition of the bispecific ocular therapeutic VIS\u2011101 through its newly\u2011formed subsidiary Visara and a licensing collaboration with Everest Medicines (HKG: 1952).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43686\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-17T07:11:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-17T07:11:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1708.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43686#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43686\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"I\u2011Mab Announces Global Transformation, NovaBridge Rebranding, and $37\u202fM Acquisition of VIS\u2011101\",\"datePublished\":\"2025-10-17T07:11:51+00:00\",\"dateModified\":\"2025-10-17T07:11:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43686\"},\"wordCount\":401,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43686#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1708.webp\",\"keywords\":[\"Everest Medicines\",\"HKG: 1952\",\"I-MAB Biopharma\",\"IPO\",\"Multi-specific antibodies\",\"NASDAQ: IMAB\",\"NovaBridge Biosciences\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43686#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43686\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43686\",\"name\":\"I\u2011Mab Announces Global Transformation, NovaBridge Rebranding, and $37\u202fM Acquisition of VIS\u2011101 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43686#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43686#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1708.webp\",\"datePublished\":\"2025-10-17T07:11:51+00:00\",\"dateModified\":\"2025-10-17T07:11:52+00:00\",\"description\":\"I\u2011MAB Biopharma (NASDAQ: IMAB), a public company under the CBC Group, today revealed a strategic overhaul to become a global biotechnology platform. The company will rename itself NovaBridge Biosciences and pursue a dual initial public offering (IPO) on the Nasdaq and the Hong Kong Stock Exchange (HKEX). Concurrently, NovaBridge announced the acquisition of the bispecific ocular therapeutic VIS\u2011101 through its newly\u2011formed subsidiary Visara and a licensing collaboration with Everest Medicines (HKG: 1952).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43686#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43686\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43686#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1708.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1708.webp\",\"width\":1080,\"height\":608,\"caption\":\"I\u2011Mab Announces Global Transformation, NovaBridge Rebranding, and $37\u202fM Acquisition of VIS\u2011101\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43686#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"I\u2011Mab Announces Global Transformation, NovaBridge Rebranding, and $37\u202fM Acquisition of VIS\u2011101\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"I\u2011Mab Announces Global Transformation, NovaBridge Rebranding, and $37\u202fM Acquisition of VIS\u2011101 - Insight, China&#039;s Pharmaceutical Industry","description":"I\u2011MAB Biopharma (NASDAQ: IMAB), a public company under the CBC Group, today revealed a strategic overhaul to become a global biotechnology platform. The company will rename itself NovaBridge Biosciences and pursue a dual initial public offering (IPO) on the Nasdaq and the Hong Kong Stock Exchange (HKEX). Concurrently, NovaBridge announced the acquisition of the bispecific ocular therapeutic VIS\u2011101 through its newly\u2011formed subsidiary Visara and a licensing collaboration with Everest Medicines (HKG: 1952).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43686","og_locale":"en_US","og_type":"article","og_title":"I\u2011Mab Announces Global Transformation, NovaBridge Rebranding, and $37\u202fM Acquisition of VIS\u2011101","og_description":"I\u2011MAB Biopharma (NASDAQ: IMAB), a public company under the CBC Group, today revealed a strategic overhaul to become a global biotechnology platform. The company will rename itself NovaBridge Biosciences and pursue a dual initial public offering (IPO) on the Nasdaq and the Hong Kong Stock Exchange (HKEX). Concurrently, NovaBridge announced the acquisition of the bispecific ocular therapeutic VIS\u2011101 through its newly\u2011formed subsidiary Visara and a licensing collaboration with Everest Medicines (HKG: 1952).","og_url":"https:\/\/flcube.com\/?p=43686","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-17T07:11:51+00:00","article_modified_time":"2025-10-17T07:11:52+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1708.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43686#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43686"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"I\u2011Mab Announces Global Transformation, NovaBridge Rebranding, and $37\u202fM Acquisition of VIS\u2011101","datePublished":"2025-10-17T07:11:51+00:00","dateModified":"2025-10-17T07:11:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43686"},"wordCount":401,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43686#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1708.webp","keywords":["Everest Medicines","HKG: 1952","I-MAB Biopharma","IPO","Multi-specific antibodies","NASDAQ: IMAB","NovaBridge Biosciences"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43686#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43686","url":"https:\/\/flcube.com\/?p=43686","name":"I\u2011Mab Announces Global Transformation, NovaBridge Rebranding, and $37\u202fM Acquisition of VIS\u2011101 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43686#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43686#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1708.webp","datePublished":"2025-10-17T07:11:51+00:00","dateModified":"2025-10-17T07:11:52+00:00","description":"I\u2011MAB Biopharma (NASDAQ: IMAB), a public company under the CBC Group, today revealed a strategic overhaul to become a global biotechnology platform. The company will rename itself NovaBridge Biosciences and pursue a dual initial public offering (IPO) on the Nasdaq and the Hong Kong Stock Exchange (HKEX). Concurrently, NovaBridge announced the acquisition of the bispecific ocular therapeutic VIS\u2011101 through its newly\u2011formed subsidiary Visara and a licensing collaboration with Everest Medicines (HKG: 1952).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43686#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43686"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43686#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1708.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1708.webp","width":1080,"height":608,"caption":"I\u2011Mab Announces Global Transformation, NovaBridge Rebranding, and $37\u202fM Acquisition of VIS\u2011101"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43686#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"I\u2011Mab Announces Global Transformation, NovaBridge Rebranding, and $37\u202fM Acquisition of VIS\u2011101"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1708.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43686","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43686"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43686\/revisions"}],"predecessor-version":[{"id":43691,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43686\/revisions\/43691"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43690"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43686"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43686"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43686"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}